Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study of 99,000 people tests Paxlovid's Real-World power against severe COVID

NCT ID NCT07261085

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study looks at health records from about 99,000 adults in Ontario who had COVID-19 and visited a pharmacist. It compares those who got Paxlovid (nirmatrelvir-ritonavir) with those who didn't, to see if the drug lowers the chance of hospitalization, ICU admission, or death within 30 to 60 days. The goal is to understand how well Paxlovid works outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Paxlovid (nirmatrelvir-ritonavir)
What this could lead to
If successful, this study could confirm that Paxlovid effectively reduces severe COVID-19 outcomes in a real-world setting, supporting its continued use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient health differences. It also only looks at data from Ontario, which may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

99,000 people

The number who actually took part.

Started

Oct 2025

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The Institute for Clinical Evaluative Sciences (ICES) data repository consists of de-identified, record-level, coded and linkable health data sets. It encompasses much of the publicly funded administrative health services records for the Ontario population eligible for universal health coverage since 1986 and integrates administrative data, registries, and surveys.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion * Record of at least 1 nirmatrelvir-ritonavir prescription and at least 1 dispensation issued by the pharmacist (Treated Cohort only) within 5 days of prescription, identified through pharmacy billing codes * Record of at least 1 assessment for nirmatrelvir-ritonavir, without a prescription issued by the pharmacist (Untreated Cohort only), OR record of at least 1 prescription for nirmatrelvir-ritonavir without dispensation (Untreated Cohort only), identified through pharmacy billing codes Exclusion * Invalid or incomplete records (e.g., missing age, missing sex, death before index) * Record of a positive PCR test for SARS-CoV-2 between 5 and 90 days prior to the index date * Had a prescription for antivirals within 3 days prior to or on the index date

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • Pfizer New York

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.